ASX Announcement



Appointment and Resignation of Company Secretary And Change of Registered Office Address

Melbourne, Australia and Minneapolis, MN – 6 June 2018 Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF), a mental health technology company today announces that Ms Melanie Leydin has been appointed as Company Secretary. Ms Leydin will commence in this role this day.

Ms Leydin has over 25 years of experience in the accounting profession and 13 years of experience as a Company Secretary for ASX Listed companies. Her extensive experience in public company responsibilities includes ASX and ASIC compliance, control and implementation of corporate governance, statutory financial reporting, reorganisation of companies and shareholder relations.

Ms Leydin replaces Mr Robert Lees who has resigned as Company Secretary effective this day. The Board acknowledges and appreciates the contribution that Mr Lees has made over the past 6 years.

The Company further advises that its registered office address has changed to:

Level 4, 100 Albert Road South Melbourne VIC 3205 Telephone +613 9692 7222 Facsimile +613 9077 9233

<Ends>

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company offers mental health solutions for business through its Corporate Health programs and is developing products to serve both the consumer and regulated healthcare provider markets. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (WA), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.otcmarkets.com and www.asx.com.au.

Further Information:	Website: www.medibio.com.au
Medibio Shareholder Enquiries:	Australian Media Enquiries:
Stephanie Ottens	Peter Taylor
Investor Relations Director	NWR Communications
Medibio Limited	peter@nwrcommunications.com.au
stephanie.ottens@medibio.com.au	T: +61 (0) 412 036 231
T: +61 434 405 400	